clinical trial · NCT05981131
Follow up of Intravesical N-803 Plus BCG in BCG-Naive Non-Muscle Invasive Bladder Cancer (NMIBC)
Non Muscle Invasive Bladder CancerN803 plus Bacillus Calmette-Guerin (BCG)
brief summary
The purpose of this clinical trial is to obtain long-term follow-up information and status of bladder cancer for patients who received study treatment in the QUILT-2.005 study.
started
Aug 17, 2023
primary completion
Aug 30, 2033
completion
Aug 30, 2033
last updated
Mar 13, 2025
detailed description
All 9 subjects that completed QUILT-2.005 phase 1b are planned to be enrolled in this study.
Thus, the maximum enrollment for this study is 9 subjects. All enrolled subjects will be followed every 12 months for life, or until withdrawal of consent, or if the Sponsor closes the study.
official title
QUILT-205: Long-Term Follow-Up of Subjects in QUILT-2.005 Phase 1b Trial of Intravesical N-803 Plus BCG in BCG-Naive Non-Muscle Invasive Bladder Cancer (NMIBC)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol